JCO global oncology · 2026
Breaking Barriers: Reducing Costs and Overcoming Challenges in BCR::ABL-1 Monitoring for Chronic Myeloid Leukemia in Brazil.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Etges Ana Paula Beck da Silva, Pires Emanuela, Pozza Caroline, Ashton-Prolla Patrícia, Astigarraga Claudia, Polanczyk Carisi
Аннотация
PURPOSE: Tyrosine kinase inhibitors are available in the Brazilian public health care system. However, reimbursement challenges limit access to molecular testing of BCR::ABL-1, which is essential for diagnosing and monitoring measurable residual disease in chronic myeloid leukemia (CML). This study estimated the costs associated with delivering the BCR::ABL-1 test in a tertiary academic reference care center in Brazil and simulated alternatives to increase patient access to the test.
METHODS: This is an economic analysis that estimates the costs based on resource consumption from a hospital to deliver a specific health care service, following the steps of the time-driven activity-based costing method at an academic reference center in Brazil. With the costs per test calculated, a scenario analysis estimated the budget impact resulting from an increase in test volume and a decrease in kit purchase cost, considering the local incidence of the disease.
RESULTS: The cost per test was R$717, and if only laboratory reagents and personnel were considered, delivering the test to one patient accounted for R$556, whereas the current reimbursement fee is R$144. The simulated scenarios indicate that by increasing the volume of tests delivered by 60% and renegotiating the acquisition cost with the supplier in the same proportion, it is possible to cover 63% of the regional demand without increasing the budget impact.
CONCLUSION: The financial and access challenges explored in this study underscore the importance of accelerating more effective and sustainable health policies in the CML field, which include access to the BCR::ABL-1 test with financial accountability.
METHODS: This is an economic analysis that estimates the costs based on resource consumption from a hospital to deliver a specific health care service, following the steps of the time-driven activity-based costing method at an academic reference center in Brazil. With the costs per test calculated, a scenario analysis estimated the budget impact resulting from an increase in test volume and a decrease in kit purchase cost, considering the local incidence of the disease.
RESULTS: The cost per test was R$717, and if only laboratory reagents and personnel were considered, delivering the test to one patient accounted for R$556, whereas the current reimbursement fee is R$144. The simulated scenarios indicate that by increasing the volume of tests delivered by 60% and renegotiating the acquisition cost with the supplier in the same proportion, it is possible to cover 63% of the regional demand without increasing the budget impact.
CONCLUSION: The financial and access challenges explored in this study underscore the importance of accelerating more effective and sustainable health policies in the CML field, which include access to the BCR::ABL-1 test with financial accountability.